**FOI Ref: 6323**

**Category(ies): Clinical - Drugs**

**Subject: Melonoma**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
* Bevacizumab (Avastin)
* Dacarbazine (DTIC)
* Trametinib (Mekinist)
* Dabrafenib (Tafinlar)
* Ipilimumab (Yervoy)
* Vemurafenib (Zelboraf)
* Nivolumab (Opdivo)
* Nivolumab + Ipilimumab (Opdivo + Yervoy)
* Pembrolizumab (Keytruda)
* Vemurafenib + cobimetinib (Zelboraf + Cotellic)
* Dabrafenib + Trametinib (Tafinlar + Mekinist)
* Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
* Other active systemic anti-cancer therapy [please state]
* Palliative care only
 | There are no Melanoma diagnoses treated with those drugs or palliative care only either as Primary tumours or Metastatic during this periodSACT - Systemic Anti-Cancer Therapy for Breast cancer patients are delivered by Weston Park; therefore, we are unable to answer this request. The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at sth.foi@nhs.net  |
| 1. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
* Ipilimumab
* Ipilimumab AND Nivolumab
* Nivolumab
* Pembrolizumab
* Dabrafenib AND Trametinib
* Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
* Other active systemic anti-cancer therapy
* Palliative care only
 | There are no Melanoma diagnoses treated with those drugs or palliative care only either as Primary tumours or Metastatic during this periodSACT - Systemic Anti-Cancer Therapy for Breast cancer patients are delivered by Weston Park; therefore, we are unable to answer this request. The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at sth.foi@nhs.net  |